Clinical and bacteriological results in urinary tract infections with single-dose Ro 13-9904 (Rocephin).
In two studies, the therapeutic effect of a single intramuscular dose of Ro 13-9904 (Rocephin) of 500 or 250 mg, respectively, was compared with a single intramuscular dose of 80 mg tobramycin in chronic urinary tract infections. 7 days after 500 mg Ro 13-9904, the infections were eradicated in 10 of the 11 patients; 7 days after 250 mg Ro 13-9904, 4 of 11 patients were reinfected with selected resistant Streptococcus faecalis. After tobramycin, 9 of 23 patients were cured. Considering enterococci as dangerous organisms in several respects we recommend a single dose of 500 mg Ro 13-9904 with a satisfactory local tolerance. Tobramycin is unsuitable for single-dose treatment.
D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002443:Ceftriaxone; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000652:urine
D002511:Cephalosporins; D002443:Ceftriaxone; D014031:Tobramycin